FMS

Fresenius Medical Care (FMS) announced the U.S. launch of its FDA-cleared multiFiltratePRO System for treating acute kidney injury in critically ill patients. The integrated continuous kidney replacement therapy system automates regional citrate anticoagulation procedures in ICUs.

FMS stock gained 3.1% following the announcement. The company plans a phased U.S. rollout targeting growth in the hospital-based acute kidney care market, with the global CRRT market expected to grow at 8.2% CAGR through 2034.

Fresenius Medical Care (FMS) is improving profitability through its FME25+ transformation program and showing promise with 5008X dialysis system adoption and value-based care expansion. However, the company faces significant headwinds including U.S. treatment volume weakness, TDAPA reimbursement reversals expected to create a €50 million headwind in 2026, China regulatory pressure, and inflation concerns. The company maintains a Zacks Rank #3 (Hold) rating with consensus expectations for 2.7% revenue growth but 5.4% earnings decline in 2026.